PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRanibizumab
Lucentis(ranibizumab)
Byooviz, Cimerli, Lucentis, Ranivisio, Susvimo, Ximluci (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat choroidal neovascularization, degenerative myopia, diabetes complications, diabetic retinopathy, and macular edema amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Byooviz, Cimerli, Lucentis, Susvimo (discontinued: Lucentis)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ranibizumab
Tradename
Proper name
Company
Number
Date
Products
LucentisranibizumabGenentechN-125156 RX2016-10-13
2 products
SusvimoranibizumabGenentechN-761197 RX2021-10-22
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
byoovizBiologic Licensing Application2025-08-22
cimerliBiologic Licensing Application2025-05-07
lucentisBiologic Licensing Application2024-11-18
susvimoBiologic Licensing Application2025-09-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
macular edema—D008269—
retinal vein occlusionEFO_1001157D012170H34.81
diabetic retinopathyEFO_0003770D003930—
Agency Specific
FDA
EMA
Expiration
Code
ranibizumab, Cimerli, Coherus BioSciences, Inc.
10/3/2023Interchangeable excl.
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA04: Ranibizumab
HCPCS
Code
Description
J2778
Injection, ranibizumab, 0.1 mg
Clinical
Clinical Trials
635 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular edemaD008269———1———1
Retinal vein occlusionD012170EFO_1001157H34.81—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRanibizumab
INNranibizumab
Description
Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 kappa-chain
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>1CZ8:H,Y|HEAVY CHAIN OF NEUTRALIZING ANTIBODY EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL >1CZ8:L,X|LIGHT CHAIN OF NEUTRALIZING ANTIBODY DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB1CZ8
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201825
ChEBI ID—
PubChem CID—
DrugBankDB01270
UNII IDZL1R02VT79 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
H0YBI8
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Byooviz – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lucentis – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lucentis – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Cimerli – Coherus Oncology
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 15,293 documents
View more details
Safety
Black-box Warning
Black-box warning for: Susvimo
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
30,015 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use